Neuroscience Therapeutic Sales Specialist

Compass Pathways appoints Kelley Boucher as Chief People Officer. Key Takeaway: Compass Pathways has appointed Kelley Boucher as Chief People Officer, effective immediately. This strategic move aims to strengthen the executive team as the company focuses on scaling its operations. The appointment aligns with Compass's mission to introduce innovative psychedelic treatments in psychiatry. Market sentiment analysis. Positive factors. * Appointment of Kelley Boucher enhances executive team. * Focus on scaling operations to support mental health care. * Commitment to introducing classic psychedelic treatments. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 2 past catalysts Cash runway Minimal dilution risk Lead asset Phase 3 · Major Depressive Disorder LONDON & NEW YORK-(BUSINESS WIRE)- $CMPS #Biotech-Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee Frequently asked questions. Who is the new Chief People Officer at Compass Pathways? Kelley Boucher has been appointed as the Chief People Officer. What is Kelley Boucher's role at Compass Pathways? She will oversee the company's human resources and support its scaling efforts. What is Compass Pathways focused on? The company is dedicated to developing new treatment options in mental health care. When did Kelley Boucher's appointment take effect? Her appointment took effect immediately.

MAHA summit highlights innovations reshaping American healthcare. Original article can be found here. (The Center Square) - The second Make America Healthy Again Summit brought together dozens of leading voices on the frontier of innovation in healthcare to tackle familiar MAHA priorities, including reversing the chronic disease epidemic and giving Americans greater control over their health. MAHA Action cofounder and President Tony Lyons underscored that mission in his opening remarks. "The chronic disease epidemic is the defining domestic crisis of our generation and ending it is our greatest shared mission," Lyons said. The summit featured back-to-back panel discussions on 14 topics, including psychedelics in medicine, democratizing care, healthcare affordability, artificial intelligence and early cancer detection. The psychedelics panel addressed an epidemic within the epidemic: mental health. Roughly one in six American adults, or 16.6%, reported currently taking antidepressants in a 2026 study led by a Harvard Medical School professor. But according to Kabir Nath, CEO of biotechnology company Compass Pathways, 4 million Americans still suffer from treatment-resistant depression, meaning conventional treatments have failed to sufficiently relieve their symptoms. "That's somebody typically who's had depression for a decade or more, has had multiple episodes, and in our studies, the current episode is lasting three to four years," Nath said. "So these are people who have not found relief from any medicines. They're at high risk for suicidality." Nath and the other panelists lead companies working to make psychedelic medicines - under medical supervision and in a controlled setting - an option for mental health treatment, as they believe the field suffers from a lack of options for patients. Selective serotonin reuptake inhibitors, more commonly known as SSRIs, became widely used in the 1990s and have remained one of the most commonly prescribed treatments for depression. "What's missing from current possibilities? Something that works quickly. Most things that exist today work slowly. Something that's durable, and something that you can take infrequently but has sustained effect," Nath said. Nath said Compass anticipates launching its psilocybin-based treatment for treatment-resistant depression in early 2027. Rob Barrow, the CEO of Definium Therapeutics, also anticipates drug approvals for next year. While AI and healthcare had a panel of its own, nearly every discussion touched on how emerging technologies are reshaping both the American healthcare system and the way individuals manage their own health. That was true in the discussion of "Prevention, Earlier Detection, and a New Future for Cancer." GRAIL is a healthcare company that has developed a simple blood test that can detect over 50 types of cancer. "We can screen for them before symptoms develop," said GRAIL CEO Josh Ofman. "It's because of advances in human genomics and advances in AI that have enabled us to do that." Ofman said those advancements could help shift healthcare from relying on snapshots of a person's health at individual points in time toward a more complete understanding of how their health changes over time. "A huge change that we could not have done five or 10 years ago in the whole diagnostics industry [is] to move away from these single snapshot views of our health to the 'movie,' which really provides us biological intelligence or biological surveillance, so that we can survey the biology of an individual over time," he said. The summit's dedicated AI and healthcare panel took those questions further, examining how the technology could change access to care, the work of healthcare professionals and the system itself. Virgílio Bento, CEO and founder of Sword, a company that delivers AI care with clinical oversight to promote whole-body health, argued that AI could expand access to healthcare by delegating work to AI and automating tasks that currently require clinicians, freeing them to devote more attention to patients and tasks that require human care. "The promise of AI healthcare is removing all barriers in terms of access to care," Bento said, pointing to the labor-intensive nature of healthcare as a barrier to care. "We believe that AI in this context can be the great equalizer in healthcare... and that's what we are working towards: building a world where the poorest person in the U.S. has access to the same high-quality healthcare as the richest person." However, Nick Perry, cofounder and CEO of Candid Health, a company working to automate medical billing and claims processing, emphasized the importance of orchestration - coordinating AI agents, other tools and processes - and being selective about where AI is best used. "The orchestration part of AI is I think a really, really important part of the problem because if AI is the only tool you use, it's a very expensive tool and it's not perfect," Perry said. "How do you make sure you're using the agents in exactly the right place in the most cost-efficient bit and the most cost-efficient way?" Syed Mohiuddin, head of healthcare at Anthropic, can envision a future where AI can do some of clinicians' work and even address physician shortages - but doesn't see that future as immediate. "To get there, very importantly, we have to make sure it actually works at every step of the way, and we have to continue to train the models to be maximally effective, and then to integrate the system. Because what you can't have is models that are good, but a system that doesn't know how to use it," Mohiuddin said. "That's where time and diffusion actually matter more than the technology itself, right?" "We have to be very backed by taking a hyper-safe, hyper-responsible approach," Mohiuddin added. "There is no industry that is more important than healthcare, and there is no more important thing we could do with this technology than allow for people to be healthier." Posted by The Center Square. The Center Square was launched in 2019 to fulfill the need for high-quality statehouse and statewide news across the United States. The focus of its work is state- and local-level government and economic reporting. A taxpayer sensibility distinguishes its work from other coverage of state and local issues. As a result of this approach, its readers are better informed about the focus of state and local government and its cost to the citizens whose tax dollars fund governmental decisions. (Note: Articles may not be original content. Reference byline for original source.)

Definium Therapeutics reports 5.1-point gap in second Phase 3 anxiety study. Panorama's week-12 result came with widespread treatment guesses; Definium plans an FDA meeting in the fourth quarter. The U.S. Food and Drug Administration is scheduled to discuss DT120 lysergide in the fourth quarter after Sept. 14 results showed a 5.1-point week-12 advantage over placebo on the Hamilton Anxiety Rating Scale (HAM-A). Definium Therapeutics, Inc. NASDAQDFTX had a US$5.42 billion market value at the Sept. 22, 4 p.m. EDT close, according to the linked Google Finance quote. The New York clinical-stage developer said its 245-person Phase 3 Panorama study in generalized anxiety disorder produced its second positive readout in that indication. Panorama followed Definium's Voyage readout in generalized anxiety disorder in August and its Emerge readout in major depressive disorder in June. DT120 remains investigational, and Definium expects to file a new drug application in the first half of 2027 after its planned FDA discussion. The trial assigned 96 adults to 100 micrograms and 97 to placebo. Another 52 were randomized to the 50-microgram arm to help reduce functional unblinding; the lower-dose arm was not designed for a statistical efficacy comparison. The controlled comparison ran for 12 weeks; a 40-week open-label extension continues. At week 12, the HAM-A score declined by an adjusted mean 9.8 points in the high-dose group against 4.7 points for placebo. The placebo-adjusted difference was 5.1 points, with a p value below 0.0001, according to the Sept. 14 release. Definium also reported meeting three key secondary efficacy endpoints, including a week-one anxiety measure and a day-two clinician severity measure. Treatment guesses complicate blinding. Definium's same-day presentation says 95 per cent of high-dose recipients and 91 per cent of lower-dose recipients correctly guessed they had received the drug. The company says the dose response supports an effect beyond treatment expectations, but the lower-dose arm was not powered to establish a separate efficacy result. The FDA's July 2026 psychedelic-trial guidance, docket FDA-2023-D-1987, warns that functional unblinding can introduce expectation bias and make an inert placebo problematic for measuring efficacy. The guidance discusses psychedelic trials generally; it does not assess Panorama. "Study results should be strongly persuasive and robust across study endpoints to overcome biases that may be introduced by functional unblinding," the FDA said in the guidance. Treatment-emergent adverse events occurred in 94.8 per cent of high-dose recipients and 62.9 per cent of placebo recipients. The presentation records two serious adverse events in the 100-microgram arm, both deemed unrelated to the drug by Definium. The company reported no suicidality signal. Participants were monitored for at least eight hours on dosing day. Definium said 94 per cent of high-dose recipients met its end-of-session criteria by hour eight, a measure of how long supervised dosing may take. FDA meeting planned for fourth quarter. Definium's Aug. 6 results put cash, cash equivalents and investments at about US$1.1 billion as of June 30. The company projected that these resources would fund operations into 2030 under its operating plan at the time. Compass Pathways plc NASDAQCMPS is developing COMP360 psilocybin for treatment-resistant depression. Compass announced on April 24 that the FDA had granted rolling submission and review for its planned application. That is a different indication and regulatory stage from Definium's planned meeting. At its pre-application meeting in the fourth quarter of 2026, Definium expects to discuss the filing it plans for the first half of 2027.